Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSCs and Teriparatide for Vertebral Compression Fracture
NCT05018637Phase 2Unknown
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of wharton's jelly mesenchymal stromal cells in vertebral compression fracture (VCF). Status: unknown.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
vertebral compression fracture (VCF)
Beyond the preview
Go deeper on NCT05018637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018637.